COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses.
Journal: 2020/April - Journal of Advanced Research
ISSN: 2090-1232
Abstract:
The coronavirus disease 19 (COVID-19) is a highly transmittable and pathogenic viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in Wuhan, China and spread around the world. Genomic analysis revealed that SARS-CoV-2 is phylogenetically related to severe acute respiratory syndrome-like (SARS-like) bat viruses, therefore bats could be the possible primary reservoir. The intermediate source of origin and transfer to humans is not known, however, the rapid human to human transfer has been confirmed widely. There is no clinically approved antiviral drug or vaccine available to be used against COVID-19. However, few broad-spectrum antiviral drugs have been evaluated against COVID-19 in clinical trials, resulted in clinical recovery. In the current review, we summarize and comparatively analyze the emergence and pathogenicity of COVID-19 infection and previous human coronaviruses severe acute respiratory syndrome coronavirus (SARS-CoV) and middle east respiratory syndrome coronavirus (MERS-CoV). We also discuss the approaches for developing effective vaccines and therapeutic combinations to cope with this viral outbreak.
Relations:
Content
Citations
(351)
References
(71)
Diseases
(2)
Chemicals
(2)
Genes
(1)
Organisms
(3)
Processes
(1)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
J Adv Res 24: 91-98

COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses

The Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, PR China
State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, PR China
College of Life Sciences, Wuhan University, Wuhan, PR China
Suliman Khan: nc.ca.sacu.sliam@81nahk.namilus
Corresponding author. nc.ca.sacu.sliam@81nahk.namilus
Contributed equally (M.A.S and S.K).
Received 2020 Mar 15; Accepted 2020 Mar 15.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Biographies

Muhammad Adnan Shereen is a PhD researcher at Wuhan University, working on Zika virus and coronavirus in the aspects of pathogenesis, drug screening and molecular mechanisms. He is an author in 8 articles published in journals with impact factor more than 5 including the recently accepted paper in Nature microbiology.

Suliman Khan has completed his PhD degree from Chinese Academy of Sciences and currently working at second affiliated hospital of Zhengzhou university as postdoctoral scientist. He has published more than 25 articles and 5 on SARS-CoV-2 in well reputed journals including Clinical microbiology and infection (CMI) and Journal of clinical microbiology (ASM-JCM) as first and corresponding author.

Abeer Kazmi is a PhD student at Wuhan University.

Nadia Bashir is a PhD student at Wuhan University working on coronaviruses. She is an author in more than 5 papers published or accepted in renowned journals.

Rabeea Siddique is a PhD student at Zhengzhou university. She has published more than 10 papers in well reputed journals as first or coauthor.

Biographies

Footnotes

Peer review under responsibility of Cairo University.

Footnotes

References

  • 1. Zhong N., Zheng B., Li Y., Poon L., Xie Z., Chan KEpidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. The Lancet. 2003;362(9393):1353–1358.[Google Scholar]
  • 2. Wang N., Shi X., Jiang L., Zhang S., Wang D., Tong PStructure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 2013;23(8):986.[Google Scholar]
  • 3. Cui J., Li F., Shi Z.-LOrigin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181–192.[Google Scholar]
  • 4. Lai C.-C., Shih T.-P., Ko W.-C., Tang H.-J., Hsueh P.-RSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;105924[Google Scholar]
  • 5. Organization WH. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020. World Health Organization, 2020.
  • 6. Peiris J., Guan Y., Yuen KSevere acute respiratory syndrome. Nat Med. 2004;10(12):S88–S97.[Google Scholar]
  • 7. Pyrc K., Berkhout B., Van Der Hoek LIdentification of new human coronaviruses. Expert Review of Anti-infective Therapy. 2007;5(2):245–253.[PubMed][Google Scholar]
  • 8. Rahman A., Sarkar ARisk factors for fatal middle east respiratory syndrome coronavirus infections in Saudi Arabia: analysis of the WHO Line List, 2013–2018. Am J Public Health. 2019;109(9):1288–1293.[Google Scholar]
  • 9. Memish Z.A., Zumla A.I., Al-Hakeem R.F., Al-Rabeeah A.A., Stephens G.MFamily cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med. 2013;368(26):2487–2494.[PubMed][Google Scholar]
  • 10. Wang C., Horby P.W., Hayden F.G., Gao G.FA novel coronavirus outbreak of global health concern. The Lancet. 2020[PubMed][Google Scholar]
  • 11. Phan L.T., Nguyen T.V., Luong Q.C., Nguyen T.V., Nguyen H.T., Le H.QImportation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med. 2020[Google Scholar]
  • 12. Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Eurosurveillance. 2020;25(4).
  • 13. Parry J. China coronavirus: cases surge as official admits human to human transmission. British Medical Journal Publishing Group; 2020. [[PubMed]
  • 14. Li Q., Guan X., Wu P., Wang X., Zhou L., Tong YEarly transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. 2020[Google Scholar]
  • 15. Kan B., Wang M., Jing H., Xu H., Jiang X., Yan MMolecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms. J Virol. 2005;79(18):11892–11900.[Google Scholar]
  • 16. Zheng B.J., Guan Y., Wong K.H., Zhou J., Wong K.L., Young B.W.YSARS-related virus predating SARS outbreak, Hong Kong. Emerg Infect Dis. 2004;10(2):176.[Google Scholar]
  • 17. Shi Z., Hu ZA review of studies on animal reservoirs of the SARS coronavirus. Virus Res. 2008;133(1):74–87.[Google Scholar]
  • 18. Paden C., Yusof M., Al Hammadi Z., Queen K., Tao Y., Eltahir YZoonotic origin and transmission of Middle East respiratory syndrome coronavirus in the UAE. Zoonoses Public Health. 2018;65(3):322–333.[Google Scholar]
  • 19. Annan A., Baldwin H.J., Corman V.M., Klose S.M., Owusu M., Nkrumah E.EHuman betacoronavirus 2c EMC/2012–related viruses in bats, Ghana and Europe. Emerg Infect Dis. 2013;19(3):456.[Google Scholar]
  • 20. Huynh J., Li S., Yount B., Smith A., Sturges L., Olsen J.CEvidence supporting a zoonotic origin of human coronavirus strain NL63. J Virol. 2012;86(23):12816–12825.[Google Scholar]
  • 21. Lau S.K., Li K.S., Tsang A.K., Lam C.S., Ahmed S., Chen HGenetic characterization of Betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications for the origin of the novel Middle East respiratory syndrome coronavirus. J Virol. 2013;87(15):8638–8650.[Google Scholar]
  • 22. Lu R., Zhao X., Li J., Niu P., Yang B., Wu HGenomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020[PubMed][Google Scholar]
  • 23. Chan J.F.-W., Yuan S., Kok K.-H., To K.K.-W., Chu H., Yang JA familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020[PubMed][Google Scholar]
  • 24. Chan J.F.-W., Kok K.-H., Zhu Z., Chu H., To K.K.-W., Yuan SGenomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting. Wuhan. Emerging Microbes & Infections. 2020;9(1):221–236.[Google Scholar]
  • 25. van Boheemen S., de Graaf M., Lauber C., Bestebroer T.M., Raj V.S., Zaki A.MGenomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio. 2012;3(6):e00473–e512.[Google Scholar]
  • 26. Raj V.S., Mou H., Smits S.L., Dekkers D.H., Müller M.A., Dijkman RDipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251–254.[Google Scholar]
  • 27. Perlman S., Netland JCoronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol. 2009;7(6):439–450.[Google Scholar]
  • 28. Glowacka I., Bertram S., Müller M.A., Allen P., Soilleux E., Pfefferle SEvidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol. 2011;85(9):4122–4134.[Google Scholar]
  • 29. Bertram S., Glowacka I., Müller M.A., Lavender H., Gnirss K., Nehlmeier ICleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. J Virol. 2011;85(24):13363–13372.[Google Scholar]
  • 30. Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-GA new coronavirus associated with human respiratory disease in China. Nature. 2020;1–5[PubMed][Google Scholar]
  • 31. Zhou P., Yang X., Wang X., Hu B., Zhang L., Zhang WA pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature [Internet]. 2020;Feb:3.[Google Scholar]
  • 32. Xu X., Chen P., Wang J., Feng J., Zhou H., Li XEvolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Science China Life Sciences. 2020;63(3):457–460.[Google Scholar]
  • 33. Wan Y., Shang J., Graham R., Baric R.S., Li FReceptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol. 2020[Google Scholar]
  • 34. Wu A., Peng Y., Huang B., Ding X., Wang X., Niu PGenome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020[PubMed][Google Scholar]
  • 35. Lu R., Zhao X., Li J., Niu P., Yang B., Wu HGenomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574.[PubMed][Google Scholar]
  • 36. Chen Y., Liu Q., Guo DEmerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020[PubMed][Google Scholar]
  • 37. Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases. 2020;91:264–6.
  • 38. Li B, Si H-R, Zhu Y, Yang X-L, Anderson DE, Shi Z-L, et al. Discovery of Bat Coronaviruses through Surveillance and Probe Capture-Based Next-Generation Sequencing. mSphere. 2020;5(1).
  • 39. Gralinski L.E., Menachery V.DReturn of the coronavirus: 2019-nCoV. Viruses. 2020;12(2):135.[Google Scholar]
  • 40. Xu X., Chen P., Wang J., Feng J., Zhou H., Li XEvolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;1–4[Google Scholar]
  • 41. Corman V.M., Ithete N.L., Richards L.R., Schoeman M.C., Preiser W., Drosten CRooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat. J Virol. 2014;88(19):11297–11303.[Google Scholar]
  • 42. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv; 2020.
  • 43. Gretebeck L.M., Subbarao KAnimal models for SARS and MERS coronaviruses. Cur Opin Virol. 2015;13:123–129.[Google Scholar]
  • 44. Cockrell A.S., Peck K.M., Yount B.L., Agnihothram S.S., Scobey T., Curnes N.RMouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome coronavirus infection. J Virol. 2014;88(9):5195–5199.[Google Scholar]
  • 45. Nagata N., Iwata N., Hasegawa H., Fukushi S., Yokoyama M., Harashima AParticipation of both host and virus factors in induction of severe acute respiratory syndrome (SARS) in F344 rats infected with SARS coronavirus. J Virol. 2007;81(4):1848–1857.[Google Scholar]
  • 46. Sheahan T.P., Sims A.C., Leist S.R., Schäfer A., Won J., Brown A.JComparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):1–14.[Google Scholar]
  • 47. Wang Z., Chen X., Lu Y., Chen F., Zhang WClinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. BioScience Trends. 2020[PubMed][Google Scholar]
  • 48. Richardson P., Griffin I., Tucker C., Smith D., Oechsle O., Phelan ABaricitinib as potential treatment for 2019-nCoV acute respiratory disease. The Lancet. 2020[Google Scholar]
  • 49. Ng C.S., Kasumba D.M., Fujita T., Luo HSpatio-temporal characterization of the antiviral activity of the XRN1-DCP1/2 aggregation against cytoplasmic RNA viruses to prevent cell death. Cell Death Differ. 2020:1–20.[PubMed][Google Scholar]
  • 50. Holshue M.L., DeBolt C., Lindquist S., Lofy K.H., Wiesman J., Bruce HFirst case of 2019 novel coronavirus in the United States. N Engl J Med. 2020[PubMed][Google Scholar]
  • 51. Wang B.X., Fish E.N. Elsevier; 2019. editors. Global virus outbreaks: Interferons as 1st responders. Seminars in immunology.
  • 52. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu MRemdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;1–3[Google Scholar]
  • 53. Agostini M.L., Andres E.L., Sims A.C., Graham R.L., Sheahan T.P., Lu XCoronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018;9(2):e00221–e318.[Google Scholar]
  • 54. Derebail V.K., Falk R.JANCA-associated vasculitis—refining therapy with plasma exchange and glucocorticoids. Mass Medical Soc. 2020[PubMed][Google Scholar]
  • 55. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. bioRxiv; 2020.
  • 56. Bisht H., Roberts A., Vogel L., Subbarao K., Moss BNeutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology. 2005;334(2):160–165.[Google Scholar]
  • 57. Kam Y.W., Kien F., Roberts A., Cheung Y.C., Lamirande E.W., Vogel LAntibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro. Vaccine. 2007;25(4):729–740.[Google Scholar]
  • 58. Yang Z-y, Kong W-p, Huang Y., Roberts A., Murphy B.R., Subbarao KA DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature. 2004;428(6982):561–564.[Google Scholar]
  • 59. Stadler K., Roberts A., Becker S., Vogel L., Eickmann M., Kolesnikova LSARS vaccine protective in mice. Emerg Infect Dis. 2005;11(8):1312.[Google Scholar]
  • 60. Kapadia S.U., Rose J.K., Lamirande E., Vogel L., Subbarao K., Roberts ALong-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology. 2005;340(2):174–182.[Google Scholar]
  • 61. Bisht H., Roberts A., Vogel L., Bukreyev A., Collins P.L., Murphy B.RSevere acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci. 2004;101(17):6641–6646.[Google Scholar]
  • 62. Buchholz U.J., Bukreyev A., Yang L., Lamirande E.W., Murphy B.R., Subbarao KContributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci. 2004;101(26):9804–9809.[Google Scholar]
  • 63. Bukreyev A., Lamirande E.W., Buchholz U.J., Vogel L.N., Elkins W.R., St Claire MMucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet. 2004;363(9427):2122–2127.[Google Scholar]
  • 64. See R.H., Zakhartchouk A.N., Petric M., Lawrence D.J., Mok C.P., Hogan R.JComparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J Gen Virol. 2006;87(3):641–650.[PubMed][Google Scholar]
  • 65. Weingartl H., Czub M., Czub S., Neufeld J., Marszal P., Gren JImmunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol. 2004;78(22):12672–12676.[Google Scholar]
  • 66. Spruth M., Kistner O., Savidis-Dacho H., Hitter E., Crowe B., Gerencer MA double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine. 2006;24(5):652–661.[Google Scholar]
  • 67. Takasuka N., Fujii H., Takahashi Y., Kasai M., Morikawa S., Itamura SA subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol. 2004;16(10):1423–1430.[Google Scholar]
  • 68. Tang L., Zhu Q., Qin E., Yu M., Ding Z., Shi HInactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol. 2004;23(6):391–394.[PubMed][Google Scholar]
  • 69. Qin E., Shi H., Tang L., Wang C., Chang G., Ding ZImmunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine. Vaccine. 2006;24(7):1028–1034.[Google Scholar]
  • 70. Zhou J., Wang W., Zhong Q., Hou W., Yang Z., Xiao S.-YImmunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. Vaccine. 2005;23(24):3202–3209.[Google Scholar]
  • 71. Qu D., Zheng B., Yao X., Guan Y., Yuan Z.-H., Zhong N.-SIntranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. Vaccine. 2005;23(7):924–931.[Google Scholar]
  • 72. McKay BLP. Drugmakers rush to develop vaccines against china virus the wall street journal. [cited 2020 28 January]; Available from: <.[PubMed]
  • 73. Inovio IP. Inovio selected by cepi to develop vaccine against new coronavirus inovio. [cited 2020 29 January]; Available from: <>.[PubMed]
  • 74. J.-H.Z.W. Lee LZ. Chinese scientists race to develop vaccine as coronavirus death toll jumps: South china morning post. [cited 2020 29 January]; Available from: <>.[PubMed]
  • 75. Cheung E. China coronavirus: Hong kong researchers have already developed vaccine but need time to test it, expert reveals: South china morning post. [cited 2020 29 January]; Available from: .[PubMed]
  • 76. Xinhua. China fast-tracks novel coronavirus vaccine development xinhua. [cited 202 29 January]; Available from: .[PubMed]
  • 77. Geo-Vax. Geovax and bravovax (wuhan, china) to collaborate on development of coronavirus vaccine. [cited 2020 3 March]; Available from: .[PubMed]
  • 78. Clover B. Clover initiates development of recombinant subunit- trimer vaccine for wuhan coronavirus (2019-ncov). [cited 2020 6 March]; Available from: .[PubMed]
  • 79. Huang Y. The SARS epidemic and its aftermath in China: a political perspective. Learning from SARS: Preparing for the next disease outbreak; 2004. p. 116–36.
  • 80. Holmes K.VSARS coronavirus: a new challenge for prevention and therapy. J Clin Investig. 2003;111(11):1605–1609.[Google Scholar]
  • 81. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu YClinical features of patients infected with 2019 novel coronavirus in Wuhan China. The Lancet. 2020[PubMed][Google Scholar]
  • 82. Perlman SAnother decade, another coronavirus. Mass Medical Soc. 2020[Google Scholar]
  • 83. Bolles M., Donaldson E., Baric RSARS-CoV and emergent coronaviruses: viral determinants of interspecies transmission. Current Opin Virol. 2011;1(6):624–634.[Google Scholar]
  • 84. Vara V. Coronavirus outbreak: The countries affected. 11 MARCH 2020; Available from: .
  • 85. Shi Y., Yi Y., Li P., Kuang T., Li L., Dong MDiagnosis of severe acute respiratory syndrome (SARS) by detection of SARS coronavirus nucleocapsid antibodies in an antigen-capturing enzyme-linked immunosorbent assay. J Clin Microbiol. 2003;41(12):5781–5782.[Google Scholar]
  • 86. Dong N, Yang X, Ye L, Chen K, Chan EW-C, Yang M, et al. Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China. bioRxiv. 2020.
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.